Proteomics investigation of OSCC-specific salivary biomarkers in a Hungarian population highlights the importance of identification of population-tailored biomarkers by Csősz, Éva et al.
RESEARCH ARTICLE
Proteomics investigation of OSCC-specific
salivary biomarkers in a Hungarian population
highlights the importance of identification of
population-tailored biomarkers
E´ va Csősz1☯‡, Pe´ter La´biscsa´k1☯‡, Gergő Kallo´1, Bernadett Ma´rkus1, Miklo´s Emri2,
Adrienn Szabo´3, Ildiko´ Tar4, Jo´zsef Tőzse´r1, Csongor Kiss5, Ildiko´ Ma´rton4*
1 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 1.
Egyetem ter, Debrecen, Hungary, 2 Department of Medical Imaging, Faculty of Medicine, University of
Debrecen, 1. Egyetem ter, Debrecen, Hungary, 3 Department of Oral and Maxillofacial Surgery, Faculty of
Dentistry, University of Debrecen, 1. Egyetem ter, Debrecen, Hungary, 4 Department of Periodontology,
Faculty of Dentistry, University of Debrecen, 1. Egyetem ter, Debrecen, Hungary, 5 Department of Pediatrics,
Faculty of Medicine, University of Debrecen, 1. Egyetem ter, Debrecen, Hungary
☯ These authors contributed equally to this work.
‡ These authors are co-first authors on this work.
* marton.ildiko@dental.unideb.hu
Abstract
Oral squamous cell carcinoma (OSCC) accounting for about 90% of malignant oral lesions
is the 6th most common malignancy worldwide. Diagnostic delay may contribute to dismal
survival rate therefore, there is a need for developing specific and sensitive biomarkers to
improve early detection. Hungarian population occupies the top places of statistics regard-
ing OSCC incidence and mortality figures therefore, we aimed at finding potential salivary
protein biomarkers suitable for the Hungarian population. In this study we investigated 14
proteins which were previously reported as significantly elevated in saliva of patients with
OSCC. In case of IL-1α, IL-1β, IL-6, IL-8, TNF-α and VEGF a Luminex-based multiplex kit
was utilized and the salivary concentrations were determined. In case of catalase, profilin-1,
S100A9, CD59, galectin-3-bindig protein, CD44, thioredoxin and keratin-19, SRM-based
targeted proteomic method was developed and the relative amount of the proteins was
determined in the saliva of patients with OSCC and controls. After several rounds of optimi-
zation and using stable isotope-containing peptides, we developed an SRM-based method
for rapid salivary protein detection. The validation of the selected potential biomarkers by
ELISA revealed salivary protein S100A9 and IL-6 as useful protein biomarkers for OSCC
detection improving the diagnostic accuracy for OSCC in the Hungarian population.A nonin-
vasive diagnostic method to detect biomarkers useful for the early diagnosis of OSCC was
developed. This can be an attractive strategy in screening saliva samples collected in a
nation-wide multi-centric study in order to decrease morbidity, mortality, to enhance survival
rate and to improve quality of life. The heterogeneity of protein biomarkers found in different
ethnic groups presented in the literature highlights the importance of identification of popula-
tion-tailored protein biomarkers.
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Introduction
With 350,000–400,000 new cases annually, oral cavity squamous cell carcinomas (OSCC) rep-
resent a major health-care problem worldwide. The increasing incidence of OSCC among
women and young and middle-aged males is particularly challenging [1–4]. Despite advances
in surgical and radiation treatments and chemotherapy, the average 5-year overall survival rate
of advanced OSCC is not much higher than 50% [5]. Hungarian women and men occupy the
top places of statistics regarding global OSCC incidence and mortality figures with an embar-
rassing fourfold elevation of overall OSCC mortality rate in Hungary by the new millennium
since the 1970-ies [6]. In contrast to other European countries where mortality rates from
OSCC started to decline after 2000, the untoward trend of rising OSCC mortality figures in
Hungary did not stop [7].
Standard diagnostic methods, i.e. expert clinical examination and histological evaluation of
suspicious areas fail to detect the majority of patients with early stage OSCC so improvement
of the diagnostic methods is required [5,8]. Salivary protein biomarkers may represent a prom-
ising tool for improving clinical outcome of patients with OSCC.
Saliva is a very dilute body fluid which contains electrolytes, nitrogenous products and pro-
teins. The protein content of saliva has been analyzed by several workgroups, and more than
2000 salivary proteins have been identified [9]. The most abundant proteins in saliva are α-
amylase, cystatins, proline rich peptides, serum albumin and mucins [9]. Besides the highly
abundant proteins, the low-abundance proteins of saliva have diagnostic values in oral diseases
like bisphosphonate-related osteonecrosis of the jaw [10] and also in systemic diseases such as
breast cancer [11]. In the past decade, several studies identified a series of proteins, mostly NF-
κB-dependent cytokines, with elevated concentration in the saliva of patients with OSCC
using antibody-based techniques, such as enzyme-linked immunosorbent assay (ELISA) as the
gold standard for protein biomarker detection [12,13]. Unfortunately, this methodology does
not allow the identification of protein biomarkers in great numbers, it is time consuming and
expensive.
Selected reaction monitoring (SRM)-based targeted proteomics allows the identification
and quantification of multiple proteins with high specificity and great detection dynamics
[14]. It can be applied practically for any kind of samples but it has high importance for the
study of different body fluids such as of patients with cancer [15].
Application of SRM-based targeted proteomics platform was already used for salivary pro-
tein biomarker detection [16] and our aim was to test if some of the potential salivary protein
biomarkers already described in scientific literature can be used in the Hungarian population
for OSCC detections.
In this prospective study we report on the detection of salivary biomarkers in accordance to
the Clinical Proteomic Technologies for Cancer (CPTC) initiative guidelines established by
the National Cancer Institute [17]. The guidelines suggest the application of SRM-based tar-
geted proteomics for verification of potential biomarkers identified in the discovery phase,
and after verification, the biomarkers can be subjected to the validation step. For validation,
only few proteins should be chosen and tested using ELISA or other antibody-based method
[17]. Candidate biomarkers reported in the literature were selected and SRM-based targeted
proteomics platform along with Luminex-based multiplex assay was used to monitor the level
of these biomarkers on a test set of samples followed by the verification of the potential bio-
markers whose level was significantly altered in the OSCC group compared to the controls by
ELISA. ELISA tests specific for the potential biomarkers were carried out on a reference set of
samples and the IL-6 and S100A9 was shown to be specific for OSCC in the studied Hungarian
patient cohort.
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Materials and methods
All the reagents used in this work were of analytical or LC-MS grade and were purchased from
Sigma-Aldrich unless stated otherwise.
Patients, sample collection
Unstimulated saliva samples were collected from 108 donors between 9 a.m. and 11 a.m. at the
Faculty of Dentistry, University of Debrecen. Patient enrollment, sample collection and pro-
cessing were carried out respecting the Declaration of Helsinki. Ethical approval was obtained
from the University of Debrecen Ethics Committee (No. 3385–2011) and the subjects gave
written informed consent. In parallel to sample collection a questionnaire containing ques-
tions on smoking habits, alcohol consumption was filled out by the patients. Patients were
asked to avoid eating, drinking, smoking, or using oral hygiene products for at least 1 hour
before sample collection.
A two-step sample collection was applied: 1) the test set (collection between 2011.06.30.-
2012.04.13.) contained 29 OSCC, 25 age-matched and 8 young controls for method develop-
ment and biomarker identifications and 2) a reference set (collection between 2013.05.09–
2016.02.29) containing 26 OSCC, 12 age-matched and 7 young controls for biomarker verifi-
cation. Saliva samples were kept on ice throughout the collection and processing—no more
than 60 minutes elapsed from sample collection to freezing. Samples of the test set were centri-
fuged at 4100 x g for 15 min at 4˚C at the Genomic Medicine and Bioinformatics Core Facility
(University of Debrecen). The supernatants were transferred to fresh tubes and the aliquots
were stored at -70˚C until further processing. The samples of the reference set were filtered
using a PVDF membrane-containing filter unit (5 μm pore size, Millipore SLSV025LS) and
the filtered saliva was aliquoted and stored at -70˚C until further processing. All donors were
patients of the University of Debrecen, Faculty of Dentistry. Consecutive patients with diag-
nosed OSCC were recruited into the study. Age-matched controls were consecutive patients
admitted to the Faculty of Dentistry for regular dental checkup. The young controls were stu-
dents of the University of Debrecen admitted to the Faculty of Dentistry for regular dental
checkup. OSCC was diagnosed by histopathological evaluation. Treatment was started based
on positive histology result and was not influenced by saliva sample collection and evaluation.
Periodontal condition was evaluated by a periodontist from Department of Periodontology;
none of the patients and healthy volunteers had diabetes mellitus, human papilloma virus
infection or any autoimmune diseases. The study population was a consecutive series of
patients and volunteers according to the above presented criteria.
Study design
In this prospective study we did not compare two laboratory methods rather we wanted to
apply the methodology of proteomics to determine proteins with high sensitivity and specific-
ity in saliva samples from patients with OSCC. Data collection was planned before sampling
and performing the examinations. Three types of examinations were applied according to the
Fig 1. During study design the CPTAC guidelines were followed: first; SRM-based biomarker
verification was carried out followed by the ELISA analysis of the three selected potential bio-
markers on larger patient cohort.
The samples for the Luminex assay and SRM-based assay were randomly selected from the
test set of samples, and the samples for validation by ELISA were also randomly selected from
the reference set of samples (S1 Table).
All the clinical evaluations of patients and controls were done by expert health care profes-
sionals (IT and AS). The laboratory examinations were done by well-trained, graduated
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molecular biologists (GK, PL, BM, and EC). This was a non-interventional study and the
results of the performed methods did not influence in any means the treatment of patients.
The sampling procedure was non-invasive and completely harmless to the study subjects.
Therefore, no adverse events were related to performing the laboratory examinations.
Cytokine assay
The multiplex immunobead Luminex x-MAP-based cytokine assay was carried out on a Cus-
tom 6plex Milliplex kit (Merck-Millipore) containing antibodies against IL-1α, IL-1β, IL-6, IL-
8, TNF-α and VEGF. 25 μl of the saliva samples of patients with OSCC and age-matched con-
trols were analyzed in duplicates. The assay was carried out based on the protocol provided by
the manufacturer and the data acquisition was done on BioPlex 2.0 Workstation (Bio-Rad)
operated by the Bioplex Manager 4.0 software. The level of IL-1α, IL-1β, IL-6, IL-8, TNF-α and
VEGF was calculated by the Bioplex Manager software based on the recorded 7-point calibra-
tion curve. For curve fitting a logistic regression model was used.
Design of SRM-based targeted proteomics method
The amino acid sequences of the examined proteins were utilized from the UniProt database
(www.uniprot.org) and were subjected to in silico trypsin digestion. In order to determine the
unique protein-specific tryptic sequences BLASTp analysis (http://blast.ncbi.nlm.nih.gov) was
carried out searching the NCBI non-redundant protein sequence database. SRM transition
design was performed by the Skyline software [18] (www.brendanx-uw1.gs.washington.edu)
on the protein-specific tryptic peptide sequences. All possible transitions of singly charged “y”
ions were tested on digested saliva samples from patients suffering from OSCC. Peptides
which gave reproducible SRM spectra with good peak shape were chosen for further analyses
and their stable isotope-labeled synthetic forms were obtained from the JPT Peptide Technolo-
gies GmbH, Germany. The quality of the synthetic peptides was assessed in our laboratory by
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0177282.g001
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mass spectrometry analyzes. The SRM spectra of all fragment ions were recorded and the two
best transitions were selected for further analyzes.
Sample preparation for mass spectrometry
200 μl filtered saliva was dried in speedvac and redissolved in 50 mM ammonium bicarbonate
buffer. Protein concentration of the samples was determined using the Bradford method [19].
Sample blocking was carried out before trypsin digestion; one randomly selected OSCC sam-
ple was grouped with one randomly selected age-matched and one young control sample and
the groups were processed together on the same day. The proteins were denatured with 6 M
urea and then reduced with 10 mM dithiothreitol. The samples were alkylated with 20 mM
iodo-acetamide and diluted with 25 mM ammonium bicarbonate in order to decrease the urea
concentration to 1 M. Trypsin digestion was performed at 37˚C overnight using MS grade
modified trypsin (ABSciex) in 1:25 enzyme to protein ratio. The digested samples were dried
in speedvac and redissolved in 1% formic acid. The samples were desalted using Pierce C18
Tips (Thermo Scientific) and the eluates were dried and dissolved in 1% formic acid.
Mass spectrometry analysis
SRM-based analysis of saliva samples were carried out on a 4000 QTRAP (ABSciex) mass spec-
trometer using a NanoSpray II MicroIon Source and controlled by the Analyst 1.4.2 software
(ABSciex). The spray voltage was 2800V, the ion source gas was 50 psi, the curtain gas was 20
psi and the source temperature was 70˚C. The dwell time was 20 msec and the cycle time was
1.7 sec allowing the collection of approximately 15 data points/chromatographic peak. The
chromatographic separation was done on an EasynLC II system (Bruker) and the peptide mix-
ture was first loaded and desalted onto an in-line trap column (5 x 0.3mm, 5μm particle size,
300 Å pore size Zorbax 300SB-C18,) followed by separation on a Zorbax 300SB-C18 analytical
column (150 mm x 75μm 3.5μm particle size, 300 Å pore size) using a 90 min acetonitrile/
water gradient with a slow increase in acetonitrile concentration from 0% to 100% during 60
min. Solvent A was 0.1% formic acid in LC water, solvent B was LC acetonitrile containing
0.1% formic acid.
For SRM analysis 20 μg digested protein spiked with the stable isotope-labeled reference
peptides was introduced to the mass spectrometer. All SRM analyses were carried out in
duplicates.
ELISA
Each saliva sample from patients with OSCC, matched control and young control subjects
were analyzed in duplicate by ELISA using Human ELISA Kit. The concentration of IL-6 and
thioredoxin (EK0410 and EK1254, respectively, Boster Biological Technology Co., Pleasanton,
USA) and S100A9 (E-EL-H1290, Elabscience Biotechnology Co., Wuhan, China) in saliva
were determined by sandwich enzyme-linked immune-sorbent assay technique according to
manufacturer’s protocol. Absorbance was measured at 450 nm and concentrations were calcu-
lated based on the recorded 6-point (thioredoxin and S100A9) and 7-point (IL-6) calibration
curves, respectively.
Data analysis
The SRM data were analyzed using the Skyline software [18]. All data where the AUC value
was less than 10 were excluded from further analyses. The Skyline data are publicly available
through the Panorama [20] web site:
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(https://panoramaweb.org/labkey/project/University%20of%20Debrecen/OSCC%20saliva/
begin.view?)
The primary data were transformed into appropriate format of MSstats R-package [21–23]
by an in-house developed software. Before the statistical analysis peptides with insufficient
amount of data across the set of samples were removed and for further analyses only those
samples were used where both technical replicates were recorded. After normalization based
on heavy standards and log2 transformation of measured abundances the group differences
were investigated by mixed-effect variance analysis [22,24] for all proteins. The groups were
used as the fixed effect and the subject level variance were modeled as random effects. The raw
p-values of group differences were adjusted by the Benjamini and Hochberg type false discov-
ery rate (FDR) method for multiple testing issues [25]. Besides the adjusted p-values the log2
fold changes, standard error and T values were examined. For evaluation of test performances
multivariate receiver operating characteristic (ROC) curve analyses [26] were constructed by
the Epi R-package [27], the accuracy and the 95% confidence intervals were calculated.
Results and discussion
Detection of salivary biomarkers which can help in the early diagnosis of OSCC is of high
importance in improving survival rates of patients with OSCC. More than 35 proteins were
identified by different groups as potential salivary biomarkers but a high variability in the
results was observed [28]. Protein biomarkers identified in one population may not necessarily
be suitable in another population. For example, IL-8 was identified as a biomarker in the USA
[12,29–32], India [13] and Serbia [33] but not in Japan and Iran [34,35]. Similarly, S100A9
proved to be a suitable OSCC biomarker in the USA but not in China [36,37]. In USA catalase
was shown to be biomarker by Hu et. al. [36] but not by de Jong et. al. [38]. The difference of
the useful biomarkers studied in different populations (Table 1) raises the question if biomark-
ers validated in one population have predictive value in another population [12,29–37,39–
50,38,51–60]. The prevalence of OSCC in Hungary is the highest in Europe so our aim was to
examine if some of the previously described OSCC biomarkers can be used in the Hungarian
population.
Based on literature data, 14 proteins were chosen and their levels were examined in the
saliva of patients with OSCC and controls originating from the North-Eastern part of Hun-
gary. Oral hygiene of age-matched controls was quite poor, characterized by the presence of
various oral inflammatory conditions, independently from the presence of OSCC, as expected
from earlier stomatoepidemiologic studies investigating this population [61,62]. Therefore,
recruitment of healthy young controls with good oral hygiene, absent from oral inflammatory
lesions was considered important.
Multiplex analyses were carried out; the level of IL-1α, IL-1β, IL-6, IL-8, TNF-α and VEGF
was examined using a custom Luminex assay taking the benefit of high sensitivity of the anti-
body-based methods. We have chosen these cytokines as far as their levels were observed to
be elevated in saliva from patients with OSCC compared to the levels observed in controls
[12,29–31,33–35,40,46]. However, in some other studies no significant changes could be
observed in the levels of IL-6 and IL-8 [29,34,35]. In order to examine the level of catalase,
profilin-1, S100A9, CD59, galectin-3-bindig protein, CD44 and keratin-19 identified as bio-
markers by different groups [36,50,54,63], targeted proteomics method was developed and
optimized.
After careful examination of the recorded metadata originating from each patient, a consid-
erable difference regarding the alcohol consumptions and smoking habits between the groups
was observed. Smoking was more abundant in patients with OSCC; they consumed more
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alcohol and more of them consumed alcohol on a daily base. Accordingly, the cariological and
periodontal status of patients was poor; the DMFT, DMFS, gingival index and plaque index
values were higher in the OSCC group compared to controls (Table 2).
Antibody-based analysis of potential OSCC salivary biomarkers
Investigating salivary appearance of proinflammatory cytokines in OSCC patients is relevant
and clinically meaningful. Cancer and chronic inflammation are interrelated with a link repre-
sented by cytokines and chemokines [66]. Both tumor cells and tumor-infiltrating immune
cells produce these regulatory compounds offering thereby multiple therapeutic targets for
immunomodulatory treatment of patients with oral and head and neck squamous cell carci-
noma [67–69]. However, the source of the investigated cytokines in the saliva of patients with
chronic oral inflammation, independent from OSCC, can be from immune cells and stimu-
lated gingival and oral mucosal tissue [70].
The saliva samples of randomly selected 26 patients and 9 age-matched controls were ana-
lyzed in duplicates and the levels of IL-1α, IL-1β, IL-6, IL-8, TNF-α and VEGF was determined
(Fig 2). In our study the levels of IL-1β, IL-6 and TNF-α were significantly elevated in the
OSCC group compared to the age-matched controls being in accordance with the previous
results reported by different groups [28,33]. Examining the distribution of data points, it was
observed that the results for IL-1β in the lower concentration range overlapped between the
OSCC and control groups and despite the significant difference they could not discriminate
between the two groups. Based on our results, it seems that among the studied cytokines only
IL-6 and TNF-α can be used as potential biomarkers in the Hungarian population.
IL-6 is expressed by OSCC tumor cells and stromal cells and it has been shown to play a
crucial role in OSCC carcinogenesis, progression and recurrence involving the IL-6, IL-6R,
STAT3 pathway [71–73]. Using a different signal transduction pathway resulting in NF-κB
activation, TNF-α has also been related to oral carcinogenesis [74]. Factors, known to be
associated with poor oral hygiene and oral inflammation, such as advanced age and smok-
ing have been shown to correlate with elevated salivary IL-6 levels [75]. Therefore, not
every cytokine may serve as a suitable diagnostic salivary biomarker of OSCC in different
populations.
The age-matched controls did not show any signs of precancerous lesions in their oral
cavity but as a result of oral inflammatory conditions we could not see any significant differ-
ences in the levels of other cytokines between the OSCC and control groups. These results
might be explained by the fact that oral hygiene in the age matched group was compromised
resulting in inflammation without any signs or symptoms of OSCC. Cheng and coworkers
have demonstrated that the levels of IL-6 and IL-8 were significantly higher in the saliva of
patients with OSCC compared to those who have chronic periodontitis [46]. Our results
confirmed these findings. IL-6 level proved to be significantly higher in patients with OSCC
than in controls exhibiting a compromised oral health condition and the same trend was
true in case of IL-8 (Fig 2). OSCC patients formed two subgroups with respect to salivary
IL-8 concentration, 7 patients had above-average and 19 patients had below average IL-8
levels. Similar to IL-1β, IL-8 level in the lower concentration range overlapped between the
OSCC and control groups. Although salivary levels of IL-8 tended to be higher in OSCC
patients than in age-matched controls, the difference in this cohort was not significant. A
similar dual distribution of serum IL-8 concentration and IL-8 expression by the tumor
cells in patients with OSCC was observed recently by Fujita et al. High serum IL-8 concen-
trations, and intensive IL-8 expression by tumor cells were significantly correlated with
poor disease outcome measures [76].
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Design of targeted proteomics method
An SRM-based targeted mass spectrometry method was designed for the examination of cata-
lase, profilin-1, thioredoxin, protein S100A9, CD59 glycoprotein, CD44 antigen, galectin-
3-bindig protein and keratin-19. The sequences were retrieved from the Uniprot database
(P04040, P07737, Q99757, P06702, P13987, P16070, Q08380, and P08727, respectively) and in
silico digested with trypsin. The tryptic peptides were searched against the NCBInr database
using the Blastp software in order to identify the peptides which are specific for the studied
proteins. Using the protein-specific sequences SRM transitions have been designed with the
help of the Skyline software. The stabile isotope-labeled (SIL) synthetic counterparts of the spe-
cific peptides were ordered and spiked into the samples in known amounts. For collision
energy (CE) and declustering potential (DP) optimization the synthetic peptides were used.
All the possible transitions of singly charged “y” ions were optimized with the help of the Sky-
line software and the best two transitions per peptide were selected. The optimized parameters
(Table 3) were used for the SRM method development and further used for the examination of
saliva samples.
In order to gain information regarding the concentration range where the peptide amount
introduced into the mass spectrometer is linear with the intensity of the signal recorded, a dilu-
tion series of approximately 60 fmol-1 pmol of SIL peptides spiked into saliva samples were
analyzed. For keratin-19 and CD44 antigen peptides no linearity could be observed. For galec-
tin 3 binding protein LASAYGAR, protein S100A9 LTWASHEK, thioredoxin VGEFSGANK
and profilin-1 TLVLLMGK peptides the curve was linear between approximately 120 fmol-0.5
pmol range, while in case of catalase LNVITVGPR, CD59 glycoprotein AGLWVYNK peptides
the linear range was slightly broader; between approximately 120 fmol-1 pmol. The thiore-
doxin TAFQEALDAAGDK peptide shows linearity between approximately 60 fmol-0.5 pmol
concentrations, while the whole studied range was covered only by protein S100A9 DLQNFLK
peptide (approximately 60 fmol-1 pmol concentrations). The broad concentration range
observed permits the study of high-amplitude changes often present in biological systems.
Fig 2. Salivary cytokine levels determined with Luminex-based multiplex assay. The concentration (pg/
ml) of the studied cytokines is indicated in case of control (CTRL) and OSCC group. Below each graph the p
value is indicated.
https://doi.org/10.1371/journal.pone.0177282.g002
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Table 3. Optimized SRM parameters used for the mass spectrometric examination of salivary proteins. The Q1 and Q3 m/z values, the type of “y” ion
used, the dwell time, declustering potential (DP) and collision energy (CE) is indicated in case of each studied peptide.
Protein Peptide Q1 (m/z) Q3 (m/z) Ion Dwell time (msec) DP CE
Catalase LNVITVGPR 484.798 642.393 y6 20 63.0 23.4
484.798 529.309 y5 20 63.0 23.4
484.798 428.261 y4 20 63.0 23.4
LNVITVGPR* 489.802 652.401 y6 20 63.0 23.4
489.802 539.317 y5 20 84.8 23.4
489.802 438.269 y4 20 84.8 23.4
CD44 antigen NDVTGGR 359.677 489.277 y5 20 84.8 16.2
359.677 390.209 y4 20 84.8 16.2
NDVTGGR* 364.681 499.286 y5 20 84.8 16.2
364.681 400.217 y4 20 84.8 16.2
TEAADLCK 425.702 620.307 y6 20 63.1 20.0
425.702 549.270 y5 20 63.1 20.0
425.702 478.232 y4 20 63.1 20.0
TEAADLCK* 429.709 628.321 y6 20 63.1 20.0
429.709 557.284 y5 20 66.6 20.0
429.709 486.247 y4 20 66.6 20.0
CD59 glycoprotein AGLQVYNK 446.747 651.346 y5 20 66.6 21.2
446.747 523.287 y4 20 66.6 21.2
AGLQVYNK* 450.755 659.360 y5 20 66.6 21.2
450.755 531.301 y4 20 66.6 21.2
Keratin-19 APSIHGGSGGR 498.254 627.295 y7 20 79.9 24.1
498.254 490.236 y6 20 79.9 24.1
498.254 433.215 y5 20 79.9 24.1
498.254 376.193 y4 20 79.9 24.1
APSIHGGSGGR* 503.258 637.304 y7 20 64.3 24.1
503.258 500.245 y6 20 64.3 24.1
503.258 443.223 y5 20 64.3 24.1
503.258 386.202 y4 20 64.3 24.1
Profilin-1 TLVLLMGK 437.775 660.411 y6 20 60.6 20.7
437.775 561.342 y5 20 60.6 20.7
437.775 448.258 y4 20 60.6 20.7
TLVLLMGK* 441.782 668.425 y6 20 60.6 20.7
441.782 569.357 y5 20 63.0 20.7
441.782 456.273 y4 20 63.0 20.7
SSFYVNGLTLGGQK 735.882 887.494 y9 20 63.0 37.7
735.882 773.451 y8 20 63.0 37.7
735.882 603.346 y6 20 84.8 37.7
SSFYVNGLTLGGQK* 739.890 895.508 y9 20 84.8 37.7
739.890 781.465 y8 20 84.8 37.7
739.890 611.360 y6 20 84.8 37.7
(Continued )
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Targeted proteomic analysis of the selected potential OSCC biomarkers
The SRM transitions for endogenous peptides and SIL counterparts were recorded and using
the amount of the SIL peptide as a reference the relative levels of endogenous peptides were
calculated. In order to assess which peptides and which transitions can be successfully utilized
in an eventual screening, saliva samples of randomly selected 15 patients with OSCC, 15
age-matched controls (MC) and 10 healthy young controls (HC) were analyzed using the
developed targeted mass spectrometry method. In all cases where the area under the curve val-
ues for the transitions were less than 10, the results were omitted and not used for further
calculations.
Some of the transitions did not give consistent results in the analyzed samples so they were
omitted from the calculations. This means that for CD44 antigen, CD59 glycoprotein, galec-
tin-3-bindig protein and keratin-19 the best transitions used during the optimization did
not provide good quality data in most of the analyzed saliva samples so they were not used for
the statistical analysis. The catalase LNVITVGPR peptide, the SSFYVNGLTLGGYK and
TLVLLMGK peptides of profilin-1, the DLYNFLK peptide from protein S100A9 and TAF-
QEALDAAGDK peptide from thioredoxin gave data of acceptable quality in most of the sam-
ples and were further used for statistical analysis.
The statistical analyses indicated no significant differences between age-matched (MC) and
healthy young (HC) controls (Fig 3A) while significant differences were observed in case of
S100A9 and thioredoxin between patients with OSCC and controls (Fig 3B–3D, Table 4).
These data suggest that these changes were specific for OSCC and were not age-dependent. In
Table 3. (Continued)
Protein Peptide Q1 (m/z) Q3 (m/z) Ion Dwell time (msec) DP CE
Protein S100A9 DLQNFLK 439.242 649.366 y5 20 84.8 20.8
439.242 521.308 y4 20 84.8 20.8
DLQNFLK* 443.249 657.380 y5 20 63.1 20.8
443.249 529.322 y4 20 63.1 20.8
LTWASHEK 486.250 757.362 y6 20 63.1 23.5
486.250 571.283 y5 20 63.1 23.5
486.250 500.246 y4 20 66.6 23.5
LTWASHEK* 490.257 765.376 y6 20 66.6 23.5
490.257 579.297 y5 20 66.6 23.5
490.257 508.260 y4 20 66.6 23.5
Thioredoxin TAFQEALDAAGDK 668.822 760.383 y8 20 66.6 33.9
668.822 689.346 y7 20 66.6 33.9
TAFQEALDAAGDK* 672.829 768.397 y8 20 79.9 33.9
672.829 697.360 y7 20 79.9 33.9
VGEFSGANK 454.727 623.314 y6 20 79.9 21.7
454.727 476.246 y5 20 79.9 21.7
VGEFSGANK* 458.734 631.328 y6 20 64.3 21.7
458.734 484.260 y5 20 64.3 21.7
Galectin-3-binding protein LASAYGAR 404.719 624.310 y6 20 64.3 18.8
404.719 466.240 y4 20 64.3 18.8
LASAYGAR* 409.723 634.318 y6 20 60.6 18.8
409.723 476.249 y4 20 60.6 18.8
* indicates the stable isotope-labeled, heavy amino acid.
https://doi.org/10.1371/journal.pone.0177282.t003
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the saliva of patients with OSCC the level of S100A9 was significantly elevated while the level
of thioredoxin was significantly reduced compared to both healthy young and age matched
controls. S100A9 is a general marker of cancerous lesions, it was identified in different tumors
including tumors of tongue, prostate, breast, lung, in colorectal cancer, gastric cancer, squa-
mous cervical cancer, etc. and it is considered as a primary target for drug development [77–
84]. Thioredoxin is part of the antioxidant system and it was shown to have increased expres-
sion in tumor samples [85–87]. We do not have information regarding the thioredoxin levels
in the salivary gland or tumor tissue itself, but it cannot be excluded that the reduction of
thioredoxin levels in saliva may arise from the fact that this protein accumulates in the tissues
resulting in a reduced secretion.
ROC analysis
The results of either the mass spectrometry-based or Luminex-based experiments provided infor-
mation about the changes of the studied proteins in patients with OSCC compared to those in
Fig 3. Quantitative analysis of salivary proteins by SRM. The log2 fold change in case of thioredoxin,
S100A9, profilin and catalase is shown. The comparison between the (A) age matched controls (MC) and
healthy controls (HC), (B) OSCC group and healthy control (HC) group, (C) OSCC group and age matched
(MC) group and (D) OSCC group and both healthy and matched control groups is indicated. * indicates
significant change, p<0.05.
https://doi.org/10.1371/journal.pone.0177282.g003
Table 4. Results of mixed-effect variance analysis of OSCC and MC group differences. The log2 fold change (logFC) standard error (SE), T values
(Tvalue) and the FDR corrected p-values are shown.
Protein Log2FC SE Tvalue Adjusted
p-value
Catalase -0.14 0.25 -0.56 0.66
Profilin-1 0.07 0.17 0.44 0.66
S100A9 2.09 0.41 5.14 <0.0001
Thioredoxin -1.10 0.39 -2.79 0.01
https://doi.org/10.1371/journal.pone.0177282.t004
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the controls. To test which proteins with a significant difference between the studied groups can
be used as possible biomarkers, a ROC curve analysis was performed and the area under the
curve (AUC) was calculated. Values of AUC close to 1.0 suggest a perfectly performing bio-
marker; while values close to 0.5 indicate that the biomarker performs not better than random.
In our experiments the AUC value for S100A9 was 0.74 (accuracy 0.75, 95% confidence inter-
val: 0.55–0.96) and for thioredoxin 0.73 (accuracy 0.79, 95% confidence interval: 0.61–0.96) sug-
gesting equally performing potential biomarkers (Fig 4). In order to examine the sensitivity and
specificity of the combination of S100A9 and thioredoxin multivariate ROC analysis was carried
out. The S100A9 and thioredoxin together performed better than alone, the AUC value was 0.80
(accuracy 0.88, 95% confidence interval: 0.77–1.0) suggesting an additive effect of the two poten-
tial biomarkers on the discrimination of OSCC samples from the controls (Fig 4).
In the next step we wanted to examine the sensitivity and specificity of the IL-6 and TNF-α
alone or in combination. The AUC for IL-6 was 0.92 (accuracy 0.92, 95% confidence interval:
0.83–1.0) and for TNF-α was 0.77 (accuracy 0.77, 95% confidence interval: 0.6–0.93), while the
AUC for the combination of IL-6 and TNF-α was 0.91 (accuracy 0.91, 95% confidence interval:
0.83–1.0) (Fig 4). These results indicate that the IL-6 alone seems to be the best potential bio-
marker able to distinguish between the OSCC samples and controls as it was shown in most of
the studies presented in the literature (Table 1).
Verification of the potential biomarkers using ELISA
The level of IL-6, S100A9 and thioredoxin was examined using quantitative ELISA according
to the protocol provided by the manufacturers in the saliva samples of patients with OSCC,
age-matched controls and young controls. The 46 samples of the reference set were analyzed
in duplicates (Fig 5) but for the statistical analysis data for only 45 samples were used (one age-
matched control sample was excluded because of missing patient data).
Fig 4. Estimation of predictive power of possible biomarkers using ROC curve analysis. The sensitivity
(y axis) was plotted versus 1−specificity (x axis) in case of each potential biomarker alone or in combinations.
The area under the curve is indicated on each pane. The sensitivity and specificity was calculated for each
biomarkers and biomarker combination.
https://doi.org/10.1371/journal.pone.0177282.g004
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According to the validation experiments in case of IL-6 and S100A9 there was significant dif-
ference observed between the OSCC and young controls and OSCC and age-matched controls,
while in case of thioredoxin the difference was significant only between OSCC and young con-
trols. ROC analysis was performed for proteins having significantly different levels between the
OSCC and age-matched control groups. The AUC for IL-6 was 0.708 with 50% sensitivity and
100% specificity and for S100A9 the AUC was 0.463, the sensitivity was 96% and specificity was
16%. This means that despite the previous good sensitivity and specificity results obtained on the
test set, the analyses carried out on the reference set, on a larger sample cohort indicate that
either IL-6 or S100A9 alone are not well-enough performing biomarkers. However, their combi-
nation with AUC of 0.74, 67% sensitivity and 83% specificity show a well performing biomarker
combination. In order to improve the sensitivity and specificity of OSCC detection further
research should be done and extension of the analyses on larger populations would be beneficial.
Conclusion
In this study we developed and optimized an SRM-based targeted proteomic approach for
monitoring the level of salivary biomarker candidate proteins and we could identify and verify
potential salivary protein biomarkers suitable for the Hungarian population.
Four out of 14 potential salivary protein biomarkers included in our study were shown to
have significant differences between the control and OSCC groups and three of them proved
worth using as potential biomarkers for the Hungarian population. The validation of IL-6,
S100A9 and thioredoxin revealed the potential utility of combination of IL-6 and S100A9.
Our results provide further evidence to literature data demonstrating that general protein
biomarkers for OSCC which can be applied world-wide are very hard to find. It should be
Fig 5. Salivary protein levels determined with ELISA. The salivary concentration of (A) thioredoxin, (B)
S100A9 protein and (C) IL-6 is indicated in case of young healthy controls (YC), age matched controls (MC)
and OSCC group. In cases where significant difference was observed the p value is indicated. (D) ROC
analysis of the combined effect of IL-6 and S100A9 protein.
https://doi.org/10.1371/journal.pone.0177282.g005
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noted that on protein level there are discrepancies between the different studied groups which
highlights the importance of population-tailored proteomics studies to find OSCC-specific
protein biomarkers applicable for cost-effective screening purposes. In our opinion our find-
ings are of remarkable importance since the incidence of OSCC is high and shows an increas-
ing tendency not only in the old but in the young generation as well.
Supporting information
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